I

IntegriChain

Life sciences data analytics for access

Government Pricing Manager

Full-Time
No salary listed
Senior
Philadelphia, PA, USA
Remote
Business & StrategyBusiness Analysis
No H1B Sponsorship

About the job

Requirements
  • Knowledge of Microsoft Office software, including Excel, Word, PowerPoint, and Access.
  • Knowledge and experience with Model N, Revitas, iContracts, and SAP/Vistex are a plus.
  • At least 5 years of direct experience with government contracts and pricing calculations, including familiarity with rebate and chargeback processing.
  • Ability to manipulate and analyze financial data.
  • Ability to manage multiple tasks, prioritize work, and meet strict timelines.
  • Ability to interact successfully with management and customers.
Responsibilities
  • Support data preparation, validation, calculation, and analysis for government pricing and price reporting programs, including Medicaid Drug Rebate, Medicare Part B, VA Federal Supply Schedule, and PHS 340B Drug Discount.
  • Prepare and validate data for Average Manufacturer Price, Best Price, Average Sales Price, non-Federal Average Manufacturer Price, Federal Ceiling Price, Industrial Funding Fee, and Unit Rebate Amount calculations.
  • Review and maintain master data used in Government Pricing calculations.
  • Manage clients' class-of-trade hierarchy and ensure incoming transactions are mapped to the correct designation.
  • Analyze calculation results and identify sources of variances.
  • Work with clients, the Government Pricing Manager, and the technical team to resolve system, data, and process issues.
  • Document revisions and data manipulations in accordance with financial controls and standard operating procedures.
  • Ensure assigned government prices are calculated accurately and on schedule, and obtain required review, approval, and signoff before communicating prices to clients, government agencies, or internal users.
  • Maintain standard operating procedures, SOX/SOC-1 documentation, and evidence supporting price calculations.
  • Coach direct reports and lead teaching and training sessions on current and newly enacted laws and guidance.
  • Execute assigned controls, data manipulations, and process steps related to Government Pricing calculations and submissions accurately and on time.
  • Respond to pricing questions and requests from customers and the access management team.
Desired Qualifications
  • Experience with Model N, Revitas, iContracts, and SAP/Vistex.

About the company

I

IntegriChain

View
Website

IntegriChain provides data-driven analytics for the life sciences industry to improve patient access to therapies. It combines an subscription-based data platform with managed services to cover the full brand lifecycle, from pre-launch to post-market. Its platform collects and aggregates data and applies analytics to identify access obstacles and opportunities in areas like government pricing, rebates, and gross-to-net calculations, helping pharmaceutical manufacturers optimize distribution and pricing strategies. The company differentiates itself by offering an end-to-end solution that blends technology with hands-on managed services, serving a broad base of clients (more than 220 life sciences companies) and using private equity backing to expand capabilities. Its goal is to help clients remove access barriers and maximize patient access to therapies while improving commercial operations.

Company Size

501-1,000

Company Stage

Debt Financing

Total Funding

$8M

Headquarters

Philadelphia, Pennsylvania

Founded

2005

Get referred to IntegriChain

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • State Price Transparency Reporting launched October 2025 with 110 manufacturer customers.
  • IntegriChain supported more than 400 pharmaceutical customers and 220 life sciences manufacturers.
  • September 2026 speaking slots at MDRP, GTN, and Trade summits reinforce category authority.

What critics are saying

  • Model N acquired Kalderos in June 2026, intensifying 340B and GTN competition.
  • Katrina Prior v. IntegriChain ended in February 2026, exposing employment and document-sealing scrutiny.
  • A failed 2026 AI rollout would weaken ICyte differentiation against Model N and IQVIA.

What makes IntegriChain unique

  • ICyte unifies commercialization, gross-to-net, pricing, channel, and patient workflows.
  • April 2026 conversational AI beta embeds explainable analytics into regulated biopharma decisions.
  • Nordic Capital backs acquisitions, hiring, and platform expansion across 2024-2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Flexible Work Hours
  • Parental Leave
  • Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

5%
AirsMed
Sep 24th, 2026
AIRS Medical appoints Tim Murdoch as Chief Commercial Officer.

AIRS Medical appoints Tim Murdoch as Chief Commercial Officer. AIRS Medical appoints Tim Murdoch as Chief Commercial Officer to accelerate its next phase of global growth. * September 24, 2026 Veteran Adobe, Salesforce and IntegriChain executive joins the TA Associates-backed MRI intelligence company to scale its global commercial organization SEOUL, South Korea and CHICAGO, Ill. - September 24, 2026 - AIRS Medical, a global AI medical imaging company advancing MRI intelligence, today announced the appointment of Tim Murdoch as Chief Commercial Officer (CCO). Murdoch will lead AIRS Medical's commercial organization, with responsibility for go-to-market execution, the partner ecosystem, and scaling the company's commercial team globally. The appointment comes at a moment of significant momentum for AIRS Medical. The company's solutions are cleared or approved in more than 40 countries and deployed across more than 1,700 healthcare institutions, and earlier this year the company announced a strategic growth investment from TA Associates to accelerate its next phase of expansion. Murdoch brings more than 25 years of experience scaling enterprise SaaS and data-driven businesses across healthcare, life sciences and other complex industries, with executive leadership positions at Adobe, Salesforce, SAP, PTC and, most recently, IntegriChain. "MRI is becoming an intelligence platform, and our next stage is about scaling enterprise execution to match the technology," said Jason Park, Chief Executive Officer of AIRS Medical. "Tim has built and led commercial organizations at some of the most demanding enterprise technology companies in the world, and he understands what world-class go-to-market looks like in healthcare. With the foundation we have built and the backing of TA Associates, this is the right moment to bring in a leader of his experience to build our global commercial engine." Before joining AIRS Medical, Murdoch served as Chief Commercial Officer of IntegriChain, where he led the global commercial organization across sales, marketing, strategic accounts, commercial operations and industry solutions, and drove a comprehensive enterprise go-to-market transformation. Previously, he served as General Manager of Healthcare & Life Sciences at Adobe, with full P&L responsibility for the vertical; during his tenure, the business grew from approximately $35 million to more than $450 million in annual recurring revenue, and he helped launch Adobe Experience Cloud for Healthcare. His earlier career includes global strategic-account leadership at Salesforce, enterprise software leadership at SAP, and sales and regional leadership roles at PTC. "AIRS Medical has built extraordinary AI technology with the potential to reshape medical imaging. What convinced me to join is that this isn't just a compelling technology story - it's a proven platform delivering real operational and economic value, with enormous opportunity still ahead," said Tim Murdoch. "Our next chapter is about bringing that innovation to customers around the world, expanding our strategic partnerships and building a world-class commercial organization capable of delivering sustained global growth." AIRS Medical continues to expand its AI-powered MRI portfolio as healthcare organizations seek to address growing imaging demand, optimize capital investment and improve access to advanced diagnostics. SwiftMR(R) helps imaging organizations improve MRI performance across diverse scanner fleets, while SwiftSight(R) extends that foundation into quantitative and longitudinal imaging intelligence. About AIRS Medical. AIRS Medical is a global AI medical imaging company transforming MRI through deep learning. Its solutions, SwiftMR(R) and SwiftSight(R), are deployed at leading health systems and imaging networks worldwide. SwiftMR(R) is FDA-cleared, CE-marked under MDR, and approved by Korea's MFDS, Japan's PMDA, and other regulatory authorities across 40+ countries. Learn more at airsmed.com. Media contact. Cynthia Ruffino Vice President, Marketing Email: [email protected]

Yahoo Finance
Apr 27th, 2026
IntegriChain launches conversational AI beta for biopharma commercial intelligence

IntegriChain has launched a beta version of its conversational AI assistant with select biopharma partners, aiming to modernise commercial data decision-making. The beta integrates data management, analytics and execution into a single AI-ready environment, focusing on government price reporting, Medicaid rebate adjudication, channel management and specialty commercial excellence. The company has established four Domain Teams to train and validate AI resources across these areas. The AI assistant will respond to natural-language queries and provide root-cause analysis beyond traditional dashboards, with general availability planned for later this year. Built on IntegriChain's ICyte cloud-native platform, the system prioritises explainability and regulatory compliance. To support platform delivery, IntegriChain has appointed John Ristuccia as Senior Vice President of Professional Services and Support.

IntegriChain
Apr 27th, 2026
IntegriChain launches conversational AI beta for biopharma commercial intelligence.

IntegriChain launches conversational AI beta for biopharma commercial intelligence. Philadelphia, April 27, 2026 - IntegriChain has launched a beta version of its conversational AI assistant with select biopharma partners, advancing its vision to modernize how commercial data is turned into decisions. The beta marks an important step toward a unified decision intelligence layer bringing together data management, analytics, and execution in a single, AI-ready environment. Early use cases focus on high-impact areas including government price reporting, Medicaid rebate adjudication, channel management, and specialty commercial excellence. "This is not about adding AI as a feature; it's about rebuilding the intelligence layer of biopharma commercialization," said Josh Halpern, CEO of IntegriChain. "By embedding explainable, trusted AI into the foundation of the ICyte(R) platform, we're helping customers move faster, operate with confidence, and scale decision-making in an increasingly complex environment." Building trusted AI in biopharma commercial operations. IntegriChain has also established its first four Domain Teams to work with beta customers and lead the training and validation of AI resources in each of the initial subject areas. The Domain Teams draw on IntegriChain's unique depth in the subject areas across consulting, managed services, data, and technology. Together, these teams are training the AI to accurately respond to natural-language queries to explore complex questions and surface insights that go beyond dashboards to root-cause analysis, performance drivers, and cross-domain context delivered directly in workflow. These deployments are shaping a general availability release planned for later this year. IntegriChain's approach prioritizes explainability, auditability, and trust, ensuring AI-generated insights align with regulatory requirements and real-world commercial workflows. The company is embedding AI across the platform rather than treating it as a standalone feature, rebuilding the intelligence layer of biopharma commercial operations from the ground up. ICyte(R) is a cloud-native platform that unifies commercial, financial, and operational data with integrated governance, quality, and compliance controls, creating the foundation for advanced analytics and agentic automation at scale. Leadership investment supporting platform delivery. To support continued platform execution and customer adoption, IntegriChain has strengthened its leadership team with two senior hires focused on global delivery, legal leadership, and technology operations. John Ristuccia has joined IntegriChain as Senior Vice President of Professional Services and Support. With more than 25 years of experience building and scaling global SaaS and data organizations, Ristuccia leads Solutions Delivery, Data Operations, Customer Engagement and Data Implementations, ensuring customers realize full value from ICyte(R) through consistent, high-quality execution. "Great platforms deliver results only when paired with operational excellence," said Ristuccia. "Our focus is translating ICyte's AI-driven capabilities into real-world outcomes for customers at global scale." Kate Barecchia serves as Senior Vice President, Legal at IntegriChain, overseeing the company's global legal strategy, corporate governance, and compliance functions. She brings more than two decades of experience advising high-growth technology companies, with a proven track record of navigating complex regulatory environments and scaling legal operations to support business growth. Prior to joining IntegriChain, Barecchia held the role of Vice President, Deputy General Counsel, and Global Data Privacy Officer at Imperva, where she played a key role in guiding the company through its acquisition. New executive and functional roles have been established to deepen the organization's commitment to advancing AI in pharma and scaling operational capacity. About IntegriChain. IntegriChain delivers biopharma's only comprehensive data-driven commercialization platform from strategy to operational execution, connecting the commercial, financial, and operational dimensions of drug access and profitability. Its ICyte(R) platform integrates technology, data, consulting, and managed services to unify critical workflows replacing manual processes with integrated analytics and precision controls. Biopharma relies on IntegriChain to optimize patient access and net revenue performance, reduce leakage, and strengthen compliance, ensuring every life-changing therapy reaches patients with speed, affordability, and sustainability. Backed by Nordic Capital, a leading sector-specialized private equity investor with a broad portfolio in healthcare and technology. IntegriChain is headquartered in Philadelphia, PA, with a location in Pune, India. For more information, contact IntegriChain Incorporated. or follow IntegriChain Incorporated. on LinkedIn. Media contact. Brandy Jensen, Senior Director of Marketing

Business Wire
Oct 16th, 2025
IntegriChain Launches Comprehensive State Price Transparency Reporting System to Support Evolving Regulatory Landscape

IntegriChain launches comprehensive State Price Transparency Reporting system to support Evolving regulatory landscape. Meeting the Moment with a Comprehensive, Market-Leading System for Evolving State Mandates PHILADELPHIA-(BUSINESS WIRE)-IntegriChain, a leading provider of pharmaceutical revenue optimization technology and data intelligence, today announced the launch of its AI-powered State Price Transparency Reporting (SPTR) system. As state-level price transparency mandates continue to expand and evolve, IntegriChain is meeting the moment with a comprehensive, market-leading solution built on deep regulatory expertise, combined with advanced automation and real-time analytics. "This launch is a great example of how AI can simplify regulatory complexity" - Shai Fiss, CAI and CTO at IntegriChain Share Developed in close collaboration with top 20 pharmaceutical manufacturers, the new SPTR platform leverages machine learning and intelligent data pipelines to identify required reports automatically, aggregate pricing data across multiple systems, and continuously adapt to new state requirements. A unified data layer and seamless single sign-on (SSO) integration across all ICyte modules provide manufacturers with full visibility and control through a single, secure interface. With a state price transparency reporting customer base of more than 110 pharmaceutical manufacturers, IntegriChain is recognized by state regulators as the industry's most accurate and trusted SPTR vendor. IntegriChain's credibility and leadership in this space were further reinforced by the appointment of industry expert Lynetta Moore to the Oregon Rulemaking Committee, underscoring the company's direct influence in shaping public policy and regulatory frameworks. "As state-level price transparency mandates continue to expand and evolve, IntegriChain offers a comprehensive, market-leading solution. This solution is built on extensive regulatory expertise, established relationships with state agencies, and a strong compliance record, allowing IntegriChain to effectively address current industry needs," says Josh Halpern, CEO of IntegriChain. "This launch is a great example of how AI can simplify regulatory complexity," added Shai Fiss, Chief AI and Technology Officer at IntegriChain. "Our platform roadmap doesn't just automate reporting, it learns from it and is getting smarter. Our next step is to integrate NLP and anomaly detection across state submissions, transforming what used to be manual, error-prone processes into intelligent, continuously improving systems. This is how compliance becomes both smarter and faster." About IntegriChain IntegriChain is the leading provider of revenue optimization technology and insights for the Pharma industry. The company's unique combination of data management, enterprise applications, consulting, and outsourcing helps manufacturers achieve better financial results by connecting commercial execution to net revenue. IntegriChain is backed by Nordic Capital, a leading sector-specialized private equity investor with a broad portfolio in Healthcare and Technology. IntegriChain is headquartered in Philadelphia, PA, with offices in Ambler, PA, and Pune, India. For more information, visit www.integrichain.com or follow on LinkedIn. Brandy Jensen | IntegriChain | [email protected] More News From IntegriChain PHILADELPHIA-( BUSINESS WIRE )-IntegriChain, a market leader in net revenue optimization technology and insights for the life sciences industry, today announced a strategic leadership evolution within its Product and Technology organization, underscoring the company's commitment to innovation. Shai Fiss has been appointed as the new Chief AI and Technology Officer (CAIO & CTO), effective August 18, 2025. Concurrently, Brad Burget, the current Chief Technology Officer, will transition to the... PHILADELPHIA-( BUSINESS WIRE )-IntegriChain, the leading provider of revenue optimization technology and insights for the pharmaceutical industry, today announced the hiring of Clay Willis. Willis brings IntegriChain more than a decade of experience in pharmaceutical consulting and advisory, predominantly around 340B, contracting, pricing, and market access issues. "The ever-changing regulatory and pricing landscape poses a tremendous challenge to our customers, and nothing is more troublesome...

Yahoo Finance
Apr 15th, 2025
Registration Opens For Access Insights Conference 2025: The Only Pharma Conference Covering The Full Commercialization Spectrum

Agenda Focuses on Balancing Patient Access and Net Revenue Optimization Keynote Speaker Bill Roth Joins Industry Veterans, Practitioners, and Technologists PHILADELPHIA, April 15, 2025 /PRNewswire/ -- IntegriChain, the leading provider of pharma revenue optimization technology and insights, today announced the opening of registration for Access Insights Conference 2025, co-hosted with Blue Fin Group. The conference, the only event dedicated to the full spectrum of pharmaceutical commercialization, will take place October 27-29, 2025, at The Mayflower Hotel, Autograph Collection, in Washington, DC. Registration is now available on the Access Insights Conference website. (PRNewsfoto/IntegriChain) Designed for commercial, operational, and financial executives and teams at pharmaceutical manufacturers, the conference delivers high-level strategic insights alongside practical, real-world solutions. Attendees will leave with a clear roadmap to navigate the next decade of commercialization success, gaining the knowledge needed to address evolving industry challenges from strategic pre-launch planning to operational execution that optimizes both patient access and net revenue. "As pharmaceutical manufacturers confront increasing regulatory and pricing pressures, the industry's top priority is achieving a sustainable balance between patient access and net revenue optimization," said IntegriChain CEO Josh Halpern